Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
Completed
Novartis
Phase 3
2008-11-01
This study will compare the safety and efficacy of initial combination treatment with
aliskiren + amlodipine to sequential add-on treatment strategies with aliskiren or amlodipine
in patients with hypertension.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 4
2009-10-01
The investigators of this study propose to examine the relationships between STK39 (Serine
Threonine Kinase 39) genotypes and responses to salt loading and to thiazide diuretics,
hydrochlorothiazide. The investigators hypothesize that STK39 genotypes will be associated
with the outcome of both interventions and can contribute to personalized care for
hypertension.
The investigators of this study propose to examine the relationships between STK39 (Serine
Threonine Kinase 39) genotypes and responses to salt loading and to thiazide diuretics,
hydrochlorothiazide. The investigators hypothesize that STK39 genotypes will be associated
with the outcome of both interventions and can contribute to personalized care for
hypertension.
The investigators of this study propose to examine the relationships between STK39 (Serine
Threonine Kinase 39) genotypes and responses to salt loading and to thiazide diuretics,
hydrochlorothiazide. The investigators hypothesize that STK39 genotypes will be associated
with the outcome of both interventions and can contribute to personalized care for
hypertension.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
